MoonLake's nanobody delivers strong phase 3 results in psoriatic arthritis

MoonLake Immunotherapeutics reported positive topline phase 3 IZAR-1 data for biologic‑naïve psoriatic arthritis patients treated with sonelokimab, with week‑16 endpoints meeting across ACR50 (42.1%), ACR20 (66.5%), minimal disease activity (41.2%), and PASI90 in patients with skin involvement (61%), though there is no active comparator arm and topline results will be followed by blinded analyses with full data due in H1 2027; IZAR-2 and other IL-17 nanobody programs are ongoing.